Structure Therapeutics Director Gets 51,804 Stock Options at $7.37 Each

Structure Therapeutics (GPCR) reported a Form 4 filing disclosing insider trading activity by Director Sharon Tetlow on June 23, 2025.

Accepted by SEC EDGAR 06/25/2025 - 05:45 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Structure Therapeutics (GPCR) reported a Form 4 filing disclosing insider trading activity by Director Sharon Tetlow on June 23, 2025. The transaction involved the acquisition of derivative securities in the form of stock options.

Key transaction details:

• Acquired 51,804 stock options to purchase ordinary shares
• Exercise price set at $7.37 per share, based on ADS trading price
• Options expire on June 22, 2035
• Vesting schedule: Equal monthly installments over 12 months from June 23, 2025
• Full vesting accelerates to immediately prior to 2026 annual shareholder meeting

Each American Depositary Share (ADS) represents three ordinary shares of the company. The options were granted at fair market value based on the ADS trading price at the time of grant.

Insider Trade Summary

Grant/Award: 51,804 shares

Grant/Award 1 txn

Insider TETLOW SHARON

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Share Option (right to buy)	51,804	$0.00	$0.00

Holdings After Transaction: Share Option (right to buy) — 51,804 contracts (Direct)

Holdings Before and After: Share Option (right to buy), 0 to 51,804 contracts (Direct)

Footnotes (3)

1. F1. The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs").
2. F2. The shares vest in equal monthly installments over the 12 months following June 23, 2025, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2026 annual shareholder meeting,
3. F3. The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many stock options were granted to Sharon Tetlow at GPCR (Structure Therapeutics) on June 23, 2025?

Sharon Tetlow was granted 51,804 share options (right to buy) at an exercise price of $7.37 per share on June 23, 2025.

What is the vesting schedule for GPCR director Sharon Tetlow's June 2025 stock options?

The stock options vest in equal monthly installments over 12 months following June 23, 2025, with full vesting occurring no later than the day before GPCR's 2026 annual shareholder meeting.

What is the expiration date for GPCR director Sharon Tetlow's stock options granted in June 2025?

The stock options expire on June 22, 2035, giving them a 10-year term from the grant date.

What is the conversion ratio of GPCR's ordinary shares to American Depositary Shares (ADS)?

Each American Depositary Share (ADS) of Structure Therapeutics (GPCR) represents three Ordinary Shares of the company.

What position does Sharon Tetlow hold at Structure Therapeutics (GPCR)?

According to the Form 4 filing, Sharon Tetlow serves as a Director of Structure Therapeutics Inc. (GPCR).

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

TETLOW SHARON

(Last) (First) (Middle)

C/O STRUCTURE THERAPEUTICS INC.

601 GATEWAY BLVD., SUITE 900

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Structure Therapeutics Inc. [ GPCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	$7.37(1)	06/23/2025		A		51,804		(2)	06/22/2035	Ordinary Shares	51,804(3)	$0	51,804	D

Explanation of Responses:

1. The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs").

2. The shares vest in equal monthly installments over the 12 months following June 23, 2025, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2026 annual shareholder meeting,

3. The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.

	/s/ Jun Yoon, Attorney-in-Fact	06/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.